Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET

Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will host a symposium on the endocannabinoid system (“ECS”) and the therapeutic potential of targeting the ECS. The symposium will be webcasted live (details below) on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET.

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will host the event, and Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus will moderate the panel session. The panel session will feature presentations from the following experts:

	●	The ECS and resolution of inflammation;
		Charles N. Serhan, Ph.D., DSc, First Endowed Distinguished Scientist, Brigham and Woman’s Hospital, currently serving as Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Simon Gelman Professor of Anesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine
	●	The ECS and skin inflammation;
		Adam Friedman, M.D., FAAD, Interim Chair, Department of Dermatology and Professor of Dermatology, George Washington University School of Medicine and Health Sciences
	●	Potential applicability of targeting the ECS to treat autoimmune diseases: Lenabasum in systemic sclerosis;
		Jessica Gordon, M.D., Associate Professor of Medicine, Weill Cornell Medical College, Associate Attending in the Department of Rheumatology at the Hospital for Special Surgery in New York

Webcast Details